DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies by Olga M. Shatnyeva et al.
PERSPECTIVE ARTICLE
published: 04 February 2015
doi: 10.3389/fgene.2015.00011
DNA damage response and evasion from
immunosurveillance in CLL: new options for NK
cell-based immunotherapies
Olga M. Shatnyeva, Hinrich P. Hansen, Katrin S. Reiners, Maike Sauer, Maulik Vyas and
Elke Pogge von Strandmann*
Innate Immunity Group, Clinic 1 for Internal Medicine, University of Cologne, Cologne, Germany
Edited by:
Christian Reinhardt, Uniklinik Köln,
Germany
Reviewed by:
Jian-Jun Wei, Northwestern
University, USA
Massimo Broggini, Istituto di
Ricerche Farmacologiche Mario
Negri, Italy
*Correspondence:
Elke Pogge von Strandmann, Innate
Immunity Group, Clinic 1 for
Internal Medicine, University of
Cologne, Kerpener Straße 62,
50924 Cologne, Germany
e-mail: elke.pogge@uk-koeln.de
Chronic lymphocytic leukemia (CLL) is the most prominent B cell malignancy among adults
in the Western world and characterized by a clonal expansion of B cells. The patients suffer
from severe immune defects resulting in increased susceptibility to infections and failure
to generate an antitumor immune response. Defects in both, DNA damage response
(DDR) pathway and crosstalk with the tissue microenvironment have been reported to
play a crucial role for the survival of CLL cells, therapy resistance and impaired immune
response. To this end, major advances over the past years have highlighted several T cell
immune evasion mechanisms in CLL. Here, we discuss the consequences of an impaired
DDR pathway for detection and elimination of CLL cells by natural killer (NK) cells. NK
cells are considered to be a major component of the immunosurveillance in leukemia but
NK cell activity is impaired in CLL. Restoration of NK cell activity using immunoligands
and immunoconstructs in combination with the conventional chemotherapy may provide a
future perspective for CLL treatment.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is an indolent lymphopro-
liferative disorder characterized by the progressive accumulation
of monoclonal CD5+ B cells in the peripheral blood, bone mar-
row and secondary lymphoid tissues (Ghia and Hallek, 2014;
Yair et al., 2014). Another typical feature of CLL is extraordinary
high frequency of chromosomal aberrations often associated with
the DNA damage response (DDR) pathway and dysregulation
of the cell cycle (Landau et al., 2013). Recent data suggest that
defects of the DDR pathway and interaction with bystander cells
of the microenvironment are pivotal factors for CLL progression.
Prolonged DNA damage and defective repair results in the release
of DNA-HMGB1 complexes from necrotic cells and the induction
of inflammatory response that can be hijacked by CLL cells (Jia
et al., 2014).
The standard therapy of CLL which includes combined
chemotherapy and/or immunotherapy is highly efficient for the
depletion of CLL cells from the peripheral blood but not from
lymphoid tissue and bone marrow. Moreover, this might result
in the selection of resistant clones (Landau et al., 2013). Hap-
loidentical stem cell transplantation (HSCT) is an alternative
treatment but restricted to a limited group of patients due
to lack of suitable donors and may cause fatal side effects.
New successful therapeutic strategies include modulation of the
microenvironment and activation of the patient immune system
to combat cancer cells (Burger and Gribben, 2014; Yair et al.,
2014).
Direct targeting of tumor-associated antigens (TAA) on malig-
nant cells by monoclonal antibodies (mAb) is regarded as a
promising approach (Simpson and Caballero, 2014). Thus, anti-
bodies against CD20 (rituximab, Obinutuzumab), CD19 (GBR
401), CD23 (lumiliximab), or CD52 (alemtuzumab) are currently
evaluated (Robak, 2013). More recently, immunotherapies with
genetically engineered chimeric T-cell receptors (CARs), which
detect TAA, were developed (Burger and Gribben, 2014; Yair
et al., 2014). So far, T cells with specificity for the common B
cell antigens CD19, CD20, and CD23 were generated (Riches
and Gribben, 2013). Initial clinical trials revealed feasibility, and
increasingly also impressive antitumor effects.
There is emerging evidence that natural killer (NK) cells also
play a pivotal role in the immunosurveillance of CLL (Reiners
et al., 2013; Huergo-Zapico et al., 2014). Understanding of
the molecular mechanisms of evasion from NK cell-mediated
immune responses and recovery of their function will help to
develop novel treatment strategies. In this review we focus on the
role of DDR defects and the immune microenvironment in the
evasion from NK cell responses in CLL, as far as on restoration of
NK cell function using immunoligands and immunoconstructs.
THE ROLE OF DDR DEFECTS IN CLL DEVELOPMENT: IMPACT
ON ESCAPE FROM NK CELL IMMUNE RESPONSE
Recent studies have identified 20 candidate CLL driver genes
associated with core signaling pathways, including DNA repair,
cell cycle control, Notch signaling, inflammatory pathways, Wnt
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signaling, RNA splicing, and RNA processing (Landau et al.,
2013), among which mutations associated with DNA repair and
cell cycle regulation are most recurrent.
The physiological function of the DDR pathway is to detect
DNA damage, to signal its presence and to mediate DNA repair.
The proximal DDR constitutes of two major kinase branches,
the ATM/Chk2 and the ATR/Chk1 pathways. Activation of ATR,
which phosphorylates its effector kinase Chk1, is induced in
response to single-strand breaks and bulky DNA lesions. The
ATM kinase, signaling through its effector Chk2, is activated
primarily in response to DNA double-strand breaks (DSBs), such
as those induced by alkylating agents, topoisomerase inhibitors,
or ionizing radiation. Chk1 and Chk2 have a protective function
providing time to the cell to repair genotoxic lesions. Both kinase
pathways result in activation of cell cycle-arresting target genes,
DNA repair and apoptosis via p53 activation (Reinhardt and Yaffe,
2009).
Recent sequencing studies identified recurrent somatic gene
mutations in CLL patients for proteins involved in DNA damage
signaling and DNA repair, including mutations in TP53, ATM,
CHEK1, CHEK2, POT1, BRCA1, and CHD2 (Puente et al., 2011;
Quesada et al., 2011).
The ATM-Chk2-p53 signaling axis plays an important role
in regulation of apoptotic response to DNA damage in CLL,
as mutations in ATM and TP53 are enriched in patients with
secondary resistance to DNA-damaging chemotherapy (Bartkova
et al., 2005; Landau et al., 2013).
ATM gene is frequently inactivated in CLL and is associated
with defective apoptosis in response to chemotherapeutic agents
(Austen et al., 2007). ATM mutant cells exhibit impaired DNA
DSB repair. Poly (ADP-ribose) polymerase (PARP) plays a pivotal
role in a direct repair of DSBs and involved in main DNA repair
mechanisms: homologous recombination and non-homologous
end-joining (Weston et al., 2010). ATM dysfunction is associated
with significantly higher PARP activity in CLL patients, which
might mediate genomic instability and progression of the dis-
ease. In vivo studies using xenograft model of an ATM mutant
cell line demonstrated significantly reduced tumor load and an
increased survival of animals after treatment with the PARP
inhibitor Olaparib (Weston et al., 2010). Clinical studies with
Olaparib demonstrated sufficient efficacy in patients with ATM
deficient, relapsed and refractory CLL (ISRCTN34386131 DOI
10.1186/ISRCTN34386131). Deletions of the short arm of chro-
mosome 17 (del(17p)) where TP53 is located are found in 5–8%
of chemotherapy-naïve patients (Dohner et al., 2000). Mutations
of TP53 are found in 4–37% of patients with CLL, and have been
associated with very poor prognosis (ultra-high risk) in a num-
ber of studies (Zenz et al., 2010). Among cases with confirmed
del(17p), the majority show mutations in the remaining TP53
allele (>80%). Higher genomic complexity and clinical diversity
of CLL are associated with T53 mutations. Impaired DDR pro-
motes a “mutator phenotype,” which allows the acquisition of
additional genetic lesions driving transformation in CLL (Seiffert
et al., 2012).
Mutational inactivation of the DDR is an established hallmark
of CLL and associated with high genomic instability (Zenz et al.,
2010; Landau et al., 2013).
ATM appears to be a major regulator of the p53 response. They
communicate the genotoxic lesion to the apoptotic machinery but
they are frequently inactivated in CLL and are associated with
poor response to conventional chemotherapy (ten Hacken and
Burger, 2014).
The B cell receptor (BCR) pathway inhibitors in CLL have
shown high efficacy in the cases with poor chromosomal aberra-
tions such as Del (17p) or p53 mutation, known to acquire resis-
tance to standard chemotherapy. Downstream targets of the BCR
such as SYK, Bruton’s tyrosine kinase (BTK), or PI3K isoform
p110 delta have a promising anti-neoplastic activity in patients
with CLL. Responses are typically manifested by rapid regression
of enlarged lymph nodes and splenomegaly that is accompanied
by transient lymphocytosis (Burger and Gribben, 2014; Yair et al.,
2014).
Clinical trials with Idelalisib, PI3K delta isoform inhibitor,
have a dramatic and durable response in CLL patients with a
markers of poor prognosis, such as mutations in p53, ATM and
NOTCH1. Monotherapy with Idelalisib and combination with
other therapeutical agents such as Rituximab and Ofatumumab
results show good activity in CLL regardless of high-risk prognos-
tic markers (Khan et al., 2014).
Moreover, the DDR is able to alert the immune system toward
the stressed cell, mainly through the recruitment of NK cells,
which are able to identify and eliminate dangerous cells without
prior antigen-mediated stimulation (Raulet, 2006; Bryceson and
Ljunggren, 2008). NK cells do not only distinguish between “self ”
and “non-self,” but specifically seek for pathological changes in
endogenous cells. One important danger signal is the inducible
expression of ligands for cytotoxic NK cell receptors [NKG2D
(NK group 2, member D) and NCRs (natural cytotoxicity recep-
tors)] to alarm the innate immune system in response to DNA
damage (Gasser et al., 2005; Gasser and Raulet, 2006a,b,c; Gasser,
2007; Soriani et al., 2009; Fine et al., 2010; Norman et al., 2011).
Ligands for these NK cell receptors are not expressed on normal
cells but are found on cells undergoing cellular stress that causes
DNA damage including chemotherapeutics or ionizing radiation
(Raulet, 2006).
The expression of NKG2D ligands in response to genotoxic
stress and stalled DNA replication forks is induced through
canonical DDR in an ATM/ATR-dependent fashion in mouse and
human fibroblasts (Gasser et al., 2005). The NKp30 ligand BAG6
is released by stressed cells via the exosomal pathway and has
to be associated with these small membrane vesicles to properly
activate NK cells (Simhadri et al., 2008). The release of exosomes
is known to be regulated by TSAP6 in a p53-dependent manner
(Lespagnol et al., 2008). Thus, defects in the DDR such as p53
mutations may directly affect NK cell-dependent recognition and
elimination of CLL cells (Reiners et al., 2013). In line, an impaired
expression of ligands for two major activating receptors—NKG2D
and NKp30—was shown to be associated with CLL probably
explaining NK cell anergy in this disease (Figure 1; Salih et al.,
2008; Nuckel et al., 2010; Costello et al., 2012; Reiners et al., 2013).
However, mechanisms of escape from NK response in CLL are not
completely clear, but defects in NK cell activity strongly correlate
with progression of the disease (Ziegler et al., 1981; Riches and
Gribben, 2013).
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FIGURE 1 | A hypothetical model of CLL escape from NK response.
The left panel of the figure demonstrate general mechanism of the escape
from NK-cell response by CLL cells. The escape of CLL cells from the NK
cell response is regulated at different levels; (1) diminished expression
NKG2D ligands on the cell surface, (2) increased levels of ligands for
inhibitory receptors ILT2 and NKG2A/B, (3) shedding by MMPs and
production of soluble ligands for activating receptors (ULBP2, MICA, and
BAG6) NKG2D and NKp30 (Iclozan et al., 2013), which rather suppress than
activate NK cells. Indirect suppression of NK cell activity might be
regulated by MDSC and Treg cells via production of TGFβ and IL-10, which
modulate expression levels of activating receptors on the cell surface of
NK cells. The right panel of the figure is focused on the impaired DDR and
its role for the escape from NK-cell response. Induction of DDR in healthy
cells results in activation ATM-p53 axis. Activation of p53 results in cell
surface expression of NKG2D ligands and exosomal release of BAG6
following transcriptional activation of TSAP6. Cell surface expression of
NKG2D ligands and exosomal expression of BAG6 is impaired in CLL cells
due to defects in DDR.
IMMUNE MICROENVIRONMENT DRIVES CLL PROGRESSION
The tumor microenvironment plays an important role in CLL
progression. The functional components of the microenviron-
ment can be divided in three groups. The first group includes
bone marrow stromal cells (BMSC), nurse-like cells (NLC), and
follicular dendritic cells (FDCs), collectively involved in support-
ing selection, survival and proliferation of CLL cells. BMSCs send
anti-apoptotic signals via VCAM and integrins and protect CLL
cells against conventional chemotherapy (Gehrke et al., 2011).
NLC attract CLL cells by secreting CXCL12 and CXCL13 and
protect from drug induced apoptosis via CXCL12, BAFF, APRIL,
CD31, and plexin-B via activation of prosurvival cascades such
as NFκB and ERK (Burger and Gribben, 2014). Also NLCs play
important role in activation of the BCR signaling cascade. FDCs
protect CLL cells from apoptosis by direct contact resulting in
upregulation of antiapoptotic protein MCL-1 (Endo et al., 2007).
The second group is represented by regulatory T cells (Treg)
and myeloid-derived suppressor cells (MDSCs). They interfere
with the complex interaction between the immune system and
transformed cells via production of immunosuppressive soluble
factors such as TGF-β and IL-10 (D’Arena et al., 2013; Jitschin
et al., 2014).
The third group encompasses components of the immune
system, including CD4+ T, CD8+ T, and NK cells. Despite an
elevated T cell count in the peripheral blood, the T cell compart-
ment is abnormal in CLL, showing profound functional defects
and signs of chronic activation [upregulation of CD69, HLA-DR,
and CD57 and downregulation of CD28 and CD62L (Pedersen
et al., 2002; Burger and Gribben, 2014)]. CD4+ T cells stimulate
CLL cells via CD40/CD40L crosstalk to induce the production of
CCL17 and CCL22 for attracting Th2 lymphocytes (Nakayama
et al., 2004). The NK cell subset in CLL patients shows reduced
ability to attack cancer cells partly owing to diminished expression
of the activating NK receptor NKp30 on the cell surface (Costello
et al., 2012). Also, HLA-G and HLA-E on the CLL cells and high
levels of soluble/decoy ligands, for activating NK cell receptors
suppress NK cell function (Nuckel et al., 2005).
NOVEL APPROACHES FOR CLL TREATMENT: IMMUNE
CONSTRUCTS AS TOOLS TO REDIRECT NK CELLS AGAINST
TUMOR CELLS
The improved understanding of the pathology of CLL and the role
of the microenvironment resulted in the development of novel
less toxic agents (Burger and Gribben, 2014; Yair et al., 2014).
These new compounds include inhibitors aimed at BCR signaling
pathway (Pallasch and Hallek, 2014), antiapoptotic proteins (Yair
et al., 2014), mAbs (Robak, 2013), and immune-modulatory
drugs (Burger and Gribben, 2014; Yair et al., 2014).
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FIGURE 2 | Potential role of immunoligands to redirect NK cells to CLL
cells. Immunoligands with specificities for CLL cells (through CD19 or
CD20) and for NK cells [through activating receptors on NK cells such as
NKG2D, NKp30, FcγRIIIa or simultaneous NKp30 and FcγRIIIa(1–4)] can link
and activate respective immune cells even in the presence of active
immune suppression. Stimulating of either of the activating receptors on NK
cell leads to cytokine secretion (IFNγ, TNFα) and degranulation, thereby
killing tumor cells by apoptosis. Professional antigen presenting cells (APCs)
such as dendritic cells (DCs) phagocytose components of dying tumor cells
and present tumor antigens to both CD8+ and CD4+ T cells, thereby
inducing cell-mediated and humoral adaptive immunity and memory
response. Direct NK–DC crosstalk in terms of maturation of DCs and killing
of immature DCs is mainly attributed to NKG2D and NKp30 activation.
Additionally, following activation NK cells express OX40 ligand (OX40L) and
CD86 on the cell surface, which can bind to the co-stimulatory receptors
OX40 and CD28 expressed by CD4+ T cells. Direct interaction between NK
and CD4+ T cells through such co-stimulatory molecules can enhance T cell
effector functions.
Current immunotherapy for CLL is mainly intended to stimu-
late T cells in order to eliminate the tumor (Costello et al., 2012;
Burger and Gribben, 2014), whereas NK cell-based therapies
are not as advanced. Various recombinant immunoligands and
immune constructs to restore impaired NK cell activity have
been developed and analyzed pre-clinically. While both represent
recombinant constructs, the immunoligands utilize natural lig-
ands for immune receptors fused to tumor-specific single chain
variable fragment (scFv) or other antibody-derived fragments
whereas the immune constructs utilize antibody-derived compo-
nents to target both immune and target cells (Vyas et al., 2014). So
far, the activating receptors FcγRIIIa, NKG2D, and NKp30 were
used as target structures on NK cells.
FcγRIIIa (CD16a) s is one of the main NK cell-activating
receptors, which upon stimulation, mediates ADCC through
the release of granzyme and perforin (Alderson and Sondel,
2011). The clinical success of many FDA-approved mAbs (e.g.,
Rituximab) is partially attributed to NK cell-mediated ADCC
through FcγRIIIa receptor (Houot et al., 2011). Several bispecific
and trispecific immunoconstructs with one arm specific for the
human FcγRIIIa receptor have been developed. These constructs
target different tumor antigens (CD33, CD123, and CD19) and
are currently tested for effectiveness (Singer et al., 2010; Stein
et al., 2010).
NKG2D is known as the most important receptor involved
in immune evasion of CLL and other tumor cells (Huergo-
Zapico et al., 2014). Tumor cells downregulate the expression
of the ligands for NKG2D and release soluble ligands upon
induced shedding by matrix metalloproteinases (MMPs) that
block NKG2D receptor function (Huang et al., 2011; Chitadze
et al., 2013). Immunoligands containing human NKG2D ligands
have already been generated (Germain et al., 2005; Pogge von
Strandmann et al., 2006; Jachimowicz et al., 2011; Kellner et al.,
2012b; Rothe et al., 2014). One of them is a recombinant bispecific
immunoligand bearing ULBP2 ligand–scFv fusion in a single
chain format. The first construct of this kind was ULBP2-BB4,
which links NK cells and CD138+ tumor cells through the ULBP2
ligand and the BB4 scFv with specificity for the TAA CD138
(Pogge von Strandmann et al., 2006). ULBP2-BB4 successfully
activated and retargeted NK cells against multiple myeloma (MM)
tumor cell lines and primary patient tumor cells and showed
antitumor activity in a xenograft MM model. Another bispecific
protein developed consists of recombinant MICA as NKG2D
ligand chemically conjugated to Fab fragments from mAb spe-
cific for TAAs such as CD19 and CD20 (Kellner et al., 2012b).
Malignant cells, which are otherwise resistant, can be rendered
susceptible to NK cell attack by NKG2D ligand MICA in this
format (Germain et al., 2005).
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Targeting NKp30 to reactivate NK cells in CLL is most promis-
ing and feasible as novel activating ligands for NKp30 are iden-
tified recently. While BAG6 can activate NK cells via NKp30 to
induce target killing of tumor cells and immature DCs when
expressed on the surface of exosomes (Pogge von Strandmann
et al., 2007; Simhadri et al., 2008), expression of B7-H6 seems
to be more tumor-confined as it is also found on the surface
of cancer cells (Brandt et al., 2009; Matta et al., 2013). A bispe-
cific immunoligand (B7-H6-7D8) comprising the B7-H6 (NKp30
ligand) ectodomain fused to a 7D8-derived anti-CD20 scFv was
generated (Kellner et al., 2012a). The B7-H6-7D8 immunoligand
efficiently redirected NKp30-dependent NK cell mediated lysis
toward CD20+ lymphoma cells (Kellner et al., 2012a, 2013).
Furthermore, this construct enhanced the lysis of target cells when
used along with either rituximab (anti-CD20 mAb which activates
the FcgRIIIa receptor) or NKG2D activating construct ULBP2-
7D8 (Kellner et al., 2012a, 2013). The concept of synergistic
activation of NK cells by multiple activating receptors is proven
in various systems in vitro (Bryceson et al., 2006; Morgado et al.,
2011; Deguine et al., 2012) and will be applied in the next
generation of immunoligands in a triplebody format (Vyas et al.,
2014; Figure 2).
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
In the last decade a better understanding of the role of the
immune environment in progression of CLL led to new targeted
therapy options. NK cells are the first line to attack the cancer,
but their activity is highly impaired in CLL patients. Recent
studies show impressive pre-clinical responses to immunoligands
and immunoconstructs redirecting NK cells against different
cancers. Novel immune construct-mediated restoration of NK
cell functionality in CLL patients is an attractive strategy for
treatment, which might even pave the way for recovery of
patients with high risk cytogenetic aberrations and/or refractory
disease.
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